BidaskClub cut shares of Sinovac Biotech, Ltd. (NASDAQ:SVA) from a buy rating to a hold rating in a research report sent to investors on Thursday morning.

Separately, ValuEngine upgraded Sinovac Biotech from a sell rating to a hold rating in a research report on Friday, June 30th.

Sinovac Biotech (SVA) opened at 6.66 on Thursday. The stock has a 50 day moving average price of $6.46 and a 200-day moving average price of $5.79. The stock’s market cap is $379.41 million. Sinovac Biotech has a one year low of $4.60 and a one year high of $6.94.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/bidaskclub-downgrades-sinovac-biotech-ltd-nasdaqsva-to-hold.html.

Large investors have recently bought and sold shares of the stock. Eqis Capital Management Inc. raised its stake in Sinovac Biotech by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 156,779 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 983 shares during the period. Renaissance Technologies LLC raised its stake in Sinovac Biotech by 10.1% in the first quarter. Renaissance Technologies LLC now owns 1,679,490 shares of the biopharmaceutical company’s stock worth $9,623,000 after buying an additional 154,690 shares during the period. Morgan Stanley raised its stake in Sinovac Biotech by 86,309.9% in the first quarter. Morgan Stanley now owns 2,721,912 shares of the biopharmaceutical company’s stock worth $15,597,000 after buying an additional 2,718,762 shares during the period. Verity Asset Management Inc. bought a new stake in Sinovac Biotech during the first quarter worth about $158,000. Finally, Spark Investment Management LLC raised its stake in Sinovac Biotech by 62.5% in the first quarter. Spark Investment Management LLC now owns 54,600 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 21,000 shares during the period. Institutional investors and hedge funds own 37.93% of the company’s stock.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.